Bottles of antihistamine tablets recalled. See the affected products

Rising Pharma Holdings Inc. has issued a nationwide recall for cetirizine hydrochloride tablets due to potential cross-contamination. The medication, commonly used for seasonal allergies and hives, may contain traces of ranitidine. This substance is typically used for heartburn and acid indigestion, posing significant health risks to individuals with specific sensitivities.

The issue surfaced when a pharmacy technician discovered red dots on some of the tablets during routine counting. The recalled products are sold in 100-count bottles. Identified lots include GY825029, GY825030, GY825031, and GY825032. The National Drug Code for these items is 16571-401-10, with an expiration date of October 2028.

Consumers sensitive to ranitidine face the risk of serious adverse reactions if they ingest these contaminated tablets. Possible health complications include anaphylaxis, difficulty swallowing, loss of consciousness, low blood pressure, and swelling of the face or throat. While the manufacturer has not yet received reports of adverse reactions, the potential for life-threatening side effects requires immediate attention from anyone holding these bottles.

If you possess these tablets, check your bottle labels against the lot numbers provided. Contact your physician or healthcare provider immediately if you suspect you have experienced any adverse effects. For further questions regarding the recall, reach out to Rising Pharma Holdings Inc. at 1-844-874-7464 during standard business hours or send an email to their quality assurance or pharmacovigilance departments.

You can also submit reports of quality issues or adverse events to the FDA through their MedWatch program. This process involves completing a standardized form available online or by calling 1-800-332-1088. Safety remains the primary concern for distributors and regulatory officials as they continue to address this contamination event.